USPTO Examiner HELM CARALYNNE E - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18950649BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELSNovember 2024February 2025Allow310NoNo
18363526CORE-SHELL MICRONEEDLE PATCH FOR H2O2 AND PH CASCADE-TRIGGERED INSULIN DELIVERYAugust 2023January 2025Abandon1710NoNo
18225227COMPOSITIONS AND METHODS FOR TREATING EPILEPSYJuly 2023January 2024Allow620YesNo
18317436MODULATION OF SOLUBILITY, PALATABILITY, ABSORPTION, AND BIOAVAILABILITY OF MITRAGYNA SPECIOSA-DERIVED COMPOUNDS FOR ORAL AND BUCCAL DELIVERYMay 2023July 2024Abandon1520NoNo
18108038METHOD OF MAKING AN OSTEOCONDUCTIVE FIBROUS ARTICLE AND A MEDICAL IMPLANT COMPRISING SUCH OSTEOCONDUCTIVE FIBROUS ARTICLEFebruary 2023July 2024Allow1720YesNo
18093240DEPOT FORMULATIONSJanuary 2023November 2024Abandon2310NoNo
17882552DRUG DELIVERY METHODS, STRUCTURES, AND COMPOSITIONS FOR NASOLACRIMAL SYSTEMAugust 2022April 2024Abandon2010NoNo
17750865TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOFMay 2022February 2024Abandon2110NoNo
17724378COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUNDApril 2022January 2024Abandon2110NoNo
17716443SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCEApril 2022January 2025Abandon3420NoNo
17706869TOPICAL PAIN PATCHMarch 2022January 2025Abandon3310NoNo
17698451HIGH-CONCENTRATION FLUENSULFONE FORMULATIONS, THEIR USES AND PROCESSES OF PREPARATIONMarch 2022October 2024Abandon3120NoNo
17698389Curcumin SolubilisateMarch 2022January 2024Abandon2210NoNo
17693904POROUS BIOCOMPATIBLE IMPLANT WITH EXCELLENT OSSEOINTEGRATION AND METHOD FOR MANUFACTURING SAMEMarch 2022November 2024Abandon3221NoNo
17690837METHODS FOR RELIEVING BACK PAIN WITH TERMINALIA CHEBULA COMPOSITIONSMarch 2022September 2024Abandon3120NoNo
17687534METHODS OF USING RIFAMYCIN SV FOR THE TREATMENT OF SICKLE CELL DISEASEMarch 2022November 2023Abandon2110NoNo
17672651ANTIBACTERIAL OR ANTIFUNGAL COMPOSITIONFebruary 2022January 2025Allow3530NoNo
17587170INHALATION OF NITRIC OXIDEJanuary 2022October 2024Abandon3320NoNo
17581820Collagen Membrane or Matrix with Antimicrobial PropertiesJanuary 2022November 2024Abandon3421NoNo
17627474COMPOSITION AND METHODS FOR THE TREATMENT OF SKIN CONDITIONSJanuary 2022May 2025Abandon4011NoNo
17626741ORAL DISODIUM PYROPHOSPHATE FOR USE IN REDUCING CALCIFICATIONJanuary 2022December 2023Abandon2301NoNo
17569586Compositions and Methods for Treating a Disorder or Defect in Soft TissueJanuary 2022October 2023Abandon2101NoNo
17596945BEVERAGE FORTIFIED WITH FERROUS BISGLYCINATEDecember 2021February 2025Abandon3810NoNo
17596946BEVERAGE FORTIFIED WITH FERROUS BISGLYCINATEDecember 2021February 2025Abandon3810NoNo
17620571CONSTITUENT FOR PREVENTING AND/OR TREATING SKIN WOUNDSDecember 2021December 2024Allow3610YesNo
17553605Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their PreparationDecember 2021December 2024Abandon3621NoNo
17545588CRACKLING HAND SANITIZER FORMULATIONS AND ASSOCIATED METHODSDecember 2021March 2024Abandon2720YesNo
17616633NON-NATURAL INSECT PHEROMONE BLEND COMPOSITIONSDecember 2021May 2025Abandon4201NoNo
17615940BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELSDecember 2021October 2024Allow3431YesNo
17614386GLYCEROL AND SODIUM PENTABORATE BASED FORMULATION PREVENTING POSTOPERATIVE ADHESIONSNovember 2021November 2024Allow3610YesNo
17611975Use of metal ions to potentiate the therapeutic effects of arsenicNovember 2021April 2025Abandon4101NoNo
17527465Cannabinoid EmulsifierNovember 2021September 2024Allow3431YesNo
17610734AQUEOUS LIQUID COSMETICNovember 2021December 2024Allow3710YesNo
17496515BIODEGRADABLE CHITOSAN MICRONEEDLE PATCH FOR TRANSDERMAL DELIVERY FOR LIVESTOCK PAIN MANAGEMENTOctober 2021June 2025Abandon4440NoNo
17490190ANTIBACTERIAL ANTIVIRAL TREATED FABRICSSeptember 2021December 2023Abandon2601NoNo
17488787CAPSULE WITH INTERNAL DIAPHRAGM FOR IMPROVED BIOAVAILABILITYSeptember 2021April 2024Abandon3020NoNo
17399709COMPOSITIONS COMPRISING DEAD SEA WATER AND POLYSACCHARIDES AND USES THEREOF AS SKIN PROTECTANTSAugust 2021February 2024Allow3011YesNo
17398173METHOD FOR TREATING CARDIAC CONDITIONS WITH PLACENTA-DERVIVED COMPOSITIONSAugust 2021June 2024Abandon3421NoNo
17428685PHOTO-PROTECTIVE PLANT-DERIVED COMPOSITIONAugust 2021September 2024Abandon3801NoNo
17428334IMPROVED ENDOSCOPE DISINFECTANTAugust 2021June 2025Allow4670YesNo
17389719DIETARY MACRO/MICRONUTRITIONAL SUPPLEMENT FOR PATIENTS UNDERGOING KIDNEY DIALYSISJuly 2021July 2023Abandon2310NoNo
17384145ANTITHROMBOTIC COATING COMPOSITION AND ANTITHROMBOTIC COATING METHOD USING SAMEJuly 2021September 2023Abandon2510NoNo
17384198ANTIMICROBIAL COATING COMPOSITION AND ANTIMICROBIAL COATING METHOD USING SAMEJuly 2021September 2023Abandon2610NoNo
17367254Novel Isoquinoline Derivative, Preparing Method Thereof, and Pharmaceutical Composition for Preventing or Treating Autophagy Related Diseases Containing the Same as an Active IngredientJuly 2021February 2023Allow1911NoNo
17416851SPRAYING AGENT COMPRISING PESTICIDEJune 2021December 2024Allow4220YesNo
17343169PROCESS FOR MANUFACTURING PHENYLEPHRINE RESINATE PARTICLES; PHENYLEPHRINE RESINATE PARTICLES; AND USE OF PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL FORMULATIONSJune 2021September 2023Abandon2710NoNo
17292536UMECLIDINIUM AND VILANTEROL FORMULATION AND INHALERMay 2021June 2025Abandon5020NoYes
17306053SURGICAL SYSTEM AND METHODS OF USEMay 2021September 2024Allow4120YesNo
17290212COMPOSITION OF ACTIVE INGREDIENTS AS BOOSTER FOR UV-FILTERSApril 2021June 2025Abandon5020NoNo
17282332METHOD AND COMPOSITION FOR RELIEVING FATIGUE AND RESTORING ENERGYApril 2021July 2024Abandon4010NoNo
17218960COSMETIC COMPOSITION WITH GLAUCINE, RETINOL AND PEPTIDES TO COMBAT SKIN AGINGMarch 2021October 2024Abandon4240YesNo
17279886TITANIUM DIOXIDE DISPERSIONMarch 2021January 2025Abandon4620NoNo
17210747COMPOSITIONS COMPRISING CARUM CARVI AND ROSMARINUS OFFICINALIS EXTRACTS AND METHODS OF USING SAMEMarch 2021April 2025Abandon4840NoNo
17209645COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE BY CONTACT LENS MEDIATED DRUG DELIVERYMarch 2021November 2023Abandon3120NoNo
17208381Compositions and Methods for Treatment of Ocular ConditionsMarch 2021January 2025Abandon4641YesNo
17207337DEVICE AND METHOD FOR TREATING INFECTIONSMarch 2021September 2024Abandon4201NoNo
17205630TENT WITH ANTIMICROBIAL TREATMENT APPLIED THERETO AND METHOD OF IMPARTING ANTIMICROBIAL PROPERTIES TO THE TENTMarch 2021December 2023Abandon3330NoNo
17198211BIOMIMETIC ELECTRICALLY CONDUCTIVE HYALURONIC ACID-BASED HYDROGELSMarch 2021October 2023Allow3121NoNo
17196953IMPLANTABLE SUSTAINED RELEASE DEVICE AND A METHOD OF USE THEREFOR IN THE TREATMENT OF BRAIN DISORDERSMarch 2021November 2023Allow3211YesNo
17180161Kill and Protect Surface Disinfectant and Hand Sanitizer for Combatting Contact Infection SpreadFebruary 2021June 2024Abandon4020YesYes
17179078Isoproterenol Compositions and MethodsFebruary 2021July 2023Allow2850YesYes
17175172METHODS OF TREATMENT WITH BUPRENORPHINEFebruary 2021March 2023Abandon2501NoNo
17174107METHOD OF WEIGHT REGULATION USING NEBULIZED NICOTINEFebruary 2021April 2024Abandon3820NoNo
17156892PREPARATION CONTAINING 6,7-UNSATURATED-7-CARBAMOYL MORPHINAN DERIVATIVESJanuary 2021April 2025Allow5150YesNo
17150246CHEMICAL VAPOR DEPOSITION OF POLYMER COATINGS FOR CONTROLLED DRUG RELEASE, ASSEMBLIES CONTAINING SAME, AND METHODS OF PRODUCTION AND USE THEREOFJanuary 2021November 2023Abandon3420NoNo
17145056INHIBITION OF CANDIDA AURIS BIOFILM FORMATION ON MEDICAL AND ENVIRONMENTAL SURFACES BY SILVER NANOPARTICLESJanuary 2021May 2023Abandon2911NoNo
17142725SURGICAL SYSTEM AND METHODS OF USEJanuary 2021May 2024Abandon4040YesNo
17141609ZN-GA SERIES ALLOY AND ITS PREPARATION METHOD AND APPLICATIONJanuary 2021May 2023Abandon2801NoNo
17107544HYDROGEL/NANOPARTICLE COMPLEX WITH TEMPERATURE SOL-GEL TRANSITION FOR SUSTAINED DRUG RELEASENovember 2020May 2024Abandon4131NoNo
17056602ANTIMICROBIAL COMPOSITION BASED ON POLYPHENOLS AND POLYSACCHARIDES, METHOD FOR PREPARING THEREOF AND USE OF THE SAMENovember 2020April 2024Abandon4101NoNo
17053870DEPOT ADMINISTRATION OF ILOPERIDONENovember 2020May 2024Abandon4221NoNo
17050230TETRABENAZINE TRANSDERMAL DELIVERY DEVICEOctober 2020July 2024Allow4511YesNo
17069587CONDUCTIVE POLYMER MICRONEEDLE ARRAYS FOR ELECTRONICALLY-CONTROLLED DRUG RELEASEOctober 2020November 2022Allow2501YesNo
17063095DEPOT FORMULATIONSOctober 2020April 2023Abandon3010NoNo
17044920ASMT EXPRESSION PROMOTEROctober 2020December 2022Abandon2610NoNo
16971489COATINGS FOR IMPLANTABLE DEVICESAugust 2020January 2023Allow2910YesNo
16997894Nanoemulsion Compositions Comprising Saponins for Increasing BioavailabilityAugust 2020August 2024Abandon4831NoNo
16963387COMPOSITIONS AND METHODS RELATING TO AMNIONJuly 2020June 2025Abandon5941NoNo
16962009ELECTROSPUN-COATED MEDICAL DEVICESJuly 2020August 2024Abandon5050NoNo
16923495Post-Charging Of Zeolite Doped Plastics With Antimicrobial Metal IonsJuly 2020March 2022Abandon2010NoNo
16923486Post-Charging Of Zeolite Doped Plastics With Antimicrobial Metal IonsJuly 2020March 2022Abandon2010NoNo
16960524DEVICES, SYSTEMS, AND METHODS FOR TREATING INTRALUMINAL CANCER VIA CONTROLLED DELIVERY OF THERAPEUTIC AGENTSJuly 2020March 2025Allow5650YesNo
16915688Subcutaneous Biodegradable Naltrexone Implant And Accompanying Behavioral Program For Weight Loss In A PatientJune 2020February 2024Abandon4340NoNo
16888665HAIR CARE SYSTEMS AND METHODS FOR DELIVERY OF CUSTOMIZED HAIR CARE PRODUCTSMay 2020May 2025Abandon5941YesNo
16888015DETOXIFICATION AND STABILIZATION OF IMPLANTABLE OR TRANSPLANTABLE BIOLOGICAL MATERIALMay 2020April 2022Abandon2310NoNo
16768544MUCOADHESIVE NANOPARTICLE ENTRAPPED INFLUENZA VIRUS VACCINE DELIVERY SYSTEMMay 2020December 2023Abandon4241NoNo
16888585CARBON QUANTUM DOTS AND PREPARATION PROCESS AND USE THEREOFMay 2020September 2021Allow1600YesNo
16882815Applying Fluoride for Treating or Preventing Viral Infection Including SARS-CoV-2May 2020June 2022Abandon2421NoYes
16765425KIT FOR PRODUCING A BODY CARE COMPOSITIONMay 2020March 2023Abandon3440NoNo
16877055BRANCHED SATURATED HYDROCARBON COSMETIC INGREDIENTMay 2020September 2022Allow2820YesNo
16863935INHALATION OF NITRIC OXIDEApril 2020February 2022Abandon2121NoNo
16852025CATMINT OIL REPELLENT AGAINST MOSQUITOSApril 2020February 2024Abandon4651NoNo
16847275HARD SURFACE CLEANING SOLUTION WITH RAPID VIRICIDAL ACTIVITYApril 2020February 2025Allow5880YesNo
16755191CORE-SHELL MICRONEEDLE PATCH FOR H2O2 AND PH CASCADE-TRIGGERED INSULIN DELIVERYApril 2020April 2023Allow3611YesNo
16753355METHOD OF MAKING AN OSTEOCONDUCTIVE FIBROUS ARTICLE AND A MEDICAL IMPLANT COMPRISING SUCH OSTEOCONDUCTIVE FIBROUS ARTICLEApril 2020February 2024Allow4641YesNo
16753740NEW POLYMERIC EMULSIFIER AND USES THEREOF FOR THE ENCAPSULATION OF HYDROPHOBIC OR HYDROPHILIC ACTIVE COMPOUNDSApril 2020May 2023Abandon3721NoNo
16826043Implantable Drug Delivery Devices for Localized Drug DeliveryMarch 2020July 2021Allow1610YesYes
16826022IMPLANTABLE DRUG DELIVERY DEVICES FOR LOCALIZED DRUG DELIVERYMarch 2020February 2022Allow2320YesYes
16826064Implantable Drug Delivery Devices for Localized Drug DeliveryMarch 2020February 2022Allow2320YesYes
16820826TUNABLE NONFOULING SURFACE OF OLIGOETHYLENE GLYCOLMarch 2020September 2022Abandon3011NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HELM, CARALYNNE E.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
32
Examiner Affirmed
28
(87.5%)
Examiner Reversed
4
(12.5%)
Reversal Percentile
23.0%
Lower than average

What This Means

With a 12.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
127
Allowed After Appeal Filing
17
(13.4%)
Not Allowed After Appeal Filing
110
(86.6%)
Filing Benefit Percentile
13.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HELM, CARALYNNE E - Prosecution Strategy Guide

Executive Summary

Examiner HELM, CARALYNNE E works in Art Unit 1615 and has examined 775 patent applications in our dataset. With an allowance rate of 29.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.

Allowance Patterns

Examiner HELM, CARALYNNE E's allowance rate of 29.8% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HELM, CARALYNNE E receive 2.82 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HELM, CARALYNNE E is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +53.4% benefit to allowance rate for applications examined by HELM, CARALYNNE E. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 11.3% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 17.4% of cases where such amendments are filed. This entry rate is in the 13% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 55.6% of appeals filed. This is in the 22% percentile among all examiners. Of these withdrawals, 52.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 51.5% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 70% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.6% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.